

Amendments to the Claims

1. (Original) An oral sustained-release tablet comprising a pharmaceutical composition and a gel-forming material, the pharmaceutical composition containing 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide as an active ingredient.
2. (Original) The oral sustained-release tablet according to claim 1, wherein the gel-forming material is hydroxypropylmethylcellulose.
3. (Original) The oral sustained-release tablet according to claim 1, wherein the pharmaceutical composition contains 18 to 73wt% of hydroxypropylmethylcellulose.
4. (Currently amended) The oral sustained-release tablet according to claim 1, obtained by mixing a granular composition containing 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide with a composition containing a gel-forming material.~~5. The oral sustained release tablet according to claim 4, wherein 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide containing granules are manufactured by using a solution of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide.~~
5. (New) The oral sustained-release tablet according to claim 4, wherein 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide containing granules are manufactured by using a solution of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide.